Aligos Therapeutics (ALGS) Capital Leases (2019 - 2025)

Aligos Therapeutics (ALGS) has reported Capital Leases for 7 consecutive years, with $122000.0 the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Capital Leases fell 35.11% year-over-year to $122000.0; the trailing twelve-month figure through Sep 2025 stood at $122000.0 (down 35.11% YoY), and the FY2024 full-year result was $122000.0, down 47.19% from the prior year.
• Capital Leases held at $122000.0 in Q3 2025 per ALGS's latest filing, from $122000.0 in the prior quarter.
• Across five years, Capital Leases topped out at $261000.0 in Q4 2021 and bottomed at $53000.0 in Q3 2021.
• Historically, Capital Leases has averaged $175421.1 across 5 years, with a median of $188000.0 in 2023.
• The sharpest annual moves came in 2021 and 2022: Capital Leases tumbled 59.23% in 2021, then jumped 228.3% in 2022.
• Over 5 years, Capital Leases stood at $261000.0 in 2021, then retreated by 11.88% to $230000.0 in 2022, then increased by 0.43% to $231000.0 in 2023, then plunged by 47.19% to $122000.0 in 2024, then changed by 0.0% to $122000.0 in 2025.
• According to Business Quant data, Capital Leases over the past three periods registered $122000.0, $122000.0, and $122000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.